CN107334870A - A kind of composition of hypotensive and preparation method thereof - Google Patents
A kind of composition of hypotensive and preparation method thereof Download PDFInfo
- Publication number
- CN107334870A CN107334870A CN201710488515.4A CN201710488515A CN107334870A CN 107334870 A CN107334870 A CN 107334870A CN 201710488515 A CN201710488515 A CN 201710488515A CN 107334870 A CN107334870 A CN 107334870A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- hypotensive
- tea
- hawthorn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 208000001953 Hypotension Diseases 0.000 title claims abstract description 27
- 208000021822 hypotensive Diseases 0.000 title claims abstract description 27
- 230000001077 hypotensive effect Effects 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 38
- 240000000249 Morus alba Species 0.000 claims abstract description 18
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 18
- 240000001548 Camellia japonica Species 0.000 claims abstract description 17
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 17
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 17
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 17
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 17
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 17
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 17
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 17
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 17
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 17
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 17
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 17
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 17
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 17
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 17
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 17
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 17
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 16
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 5
- 230000036772 blood pressure Effects 0.000 claims description 26
- 235000015091 medicinal tea Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 239000004744 fabric Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 16
- 210000004185 liver Anatomy 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 12
- 210000000952 spleen Anatomy 0.000 abstract description 9
- 239000000796 flavoring agent Substances 0.000 abstract description 6
- 235000019634 flavors Nutrition 0.000 abstract description 6
- 230000001914 calming effect Effects 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 4
- 239000012530 fluid Substances 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract description 3
- 230000001151 other effect Effects 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 19
- 241001092040 Crataegus Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 108091006146 Channels Proteins 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 8
- 230000035488 systolic blood pressure Effects 0.000 description 8
- 230000035487 diastolic blood pressure Effects 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000007530 Essential hypertension Diseases 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 6
- 229960000830 captopril Drugs 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 206010003549 asthenia Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000010415 tropism Effects 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 241001328788 Camellia nitidissima Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 241000657480 Crataegus pinnatifida Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102100030841 AT-rich interactive domain-containing protein 4A Human genes 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- 241001657422 Camellia petelotii Species 0.000 description 1
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000008440 Crataegus cuneata Nutrition 0.000 description 1
- 244000160089 Crataegus cuneata Species 0.000 description 1
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 1
- 235000014283 Crataegus pinnatifida var major Nutrition 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 101000792933 Homo sapiens AT-rich interactive domain-containing protein 4A Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 241000282537 Mandrillus sphinx Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 241001601725 Sthenias Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000021393 food security Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of composition of hypotensive and preparation method thereof, said composition is made up of the component of following parts by weight：15 parts of golden camellia tea, 15 parts of lotus leaf, 15 parts of the root of kudzu vine, 15 parts of cassia seed, 15 parts of hawthorn, 15 parts of mulberry leaf.The composition of the present invention has clearing liver fire, calming the liver, strengthening the spleen and replenishing qi, fluid dryness and other effects, each flavour of a drug mutually cooperate with, the action characters such as too many levels, Mutiple Targets, multipath, there is the effect of preferable to hypertension, immunity of organisms can also be improved, have no toxic side effect, medicine or health food can be used as to take.
Description
Technical field
The present invention relates to medicine, field of health care food, and in particular to a kind of composition of hypotensive.
Background technology
With the change of people's living standards continue to improve and dietary structure, hypertension, high fat of blood, the trouble of hyperglycaemia
Person increases year by year.Hypertension is a kind of disease increased with systemic arterial pressure as main feature, be one kind in Adult Groups
Common angiocardiopathy, it is population of China cerebral apoplexy and incidence of coronary heart disease and the Major Risk Factors of death.China is high at present
Blood patient is up to 200,000,000, and wherein essential hypertension (EH) accounts for more than 95%, the infringement of its severe complication heart, brain, kidney, sternly
The life and health of the our people masses has been threatened again, it is seen that, active prevention and treatment hypertension are extremely urgent.At present, high blood
The pai n nursing to a variety of cardiovascular risk factors is emphasized in the treatment of pressure, and clinical treatment still lacks radical cure based on Western medicine
Medicine.Western medicine of depressurization species is various, wherein calcium-channel antagonists (CCB), angiotensin converting enzyme inhibitor (ACEI), blood vessel
Angiotensin receptor antagonist (ARB) though, beta-blocker, diuretics can effectively control blood pressure as a line antihypertensive drugs,
But single variety Treatment of Hypertension reach mark blood pressure rate is still not high enough, most hyperpietics need two or more antihypertensive drugs therapeutic alliance,
Also there are some patientss because contraindication be present and without suitable decompression scheme, and western medicine of depressurization is side effect to be present big, it is bad anti-
Answer incidence high, take stopgap measures and but hinder this problems such as, influence the quality of life of patient.
Traditional Chinese medical theory thinks that hypertension belongs to the categories such as " dizziness ", " headache ", and the essence of high blood pressure is that " this void is marked
It is real ", principle of reatment is clinical when elimnation for excess and tonification for deficiency, adjustment negative and positive, simulataneous insufficiency and excessive or sthenia symptoms caused by asthenia or by causing empty person to work as strengthening vital QI to eliminate pathogenic factors in fact
Sample should be distinguished, is weighed the relative importance, takes the circumstances into consideration to treat, reaches integrally-regulated, equilibrium between yin and yang purpose.Blood pressure traditional Chinese medicine is controlled to have more
The characteristics of target spot effect, multipath work, wide prospect is provided for the treatment of hypertension.Chinese medicine high blood pressure can
Patient symptom is obviously improved, is conceived to overall conditioning, prevents fluctuation of blood pressure to be steadily depressured, reduces Western medicine dosage and adverse reaction,
Can be under the principle effected a permanent cure, while the uncomfortable symptom of patient is eliminated, there is significant advantage.And " integration of drinking and medicinal herbs " class Chinese medicine, it is simultaneous
Nutritious and treatment two-way function, it is even more that there is certain advantage in terms of hypertension is treated.The present invention utilizes Traditional Chinese Medicine
The principle of theory on treatment hypertension, a kind of composition of hypotensive is worked out, has not yet to see relevant report.
(1) golden camellia tea, for Camellia nitidissima Camellia chrysantha (Hu) Tuyama blade, Theaceae Camellia
Camellia Section Chrysantha,《Strengthen medicine quality standard in Guangxi Zhuang Autonomous Region》Described in its have clearing heat and detoxicating, diuresis dampness removing and other effects.Root
According to Nutrition and Food Safety Office of China Disease Prevention and control Centre, Guangxi Center for Disease Control and Prevention, Guangxi Zhuang
Autonomous region of race sanitary monitoring test center, the nutrition of Beijing disease prevention and control center and food security institute, Guangxi Zhuang Autonomous Region
The authoritative institutions such as analysis testing research center, Colleges Of Traditional Chinese Medicine Of Guangxi, Guangxi Agriculture College experimental center, which examine, to be shown：Camellia nitidissima effect
With expansion coronary vasodilator, reduce hypertension, enhancing heart contraction or heart collecting moving number, quench the thirst only phlegm, anti-inflammation, anti-capillary
The effect such as fragility of blood vessels and abnormal permeability, antitumor, hepatic cholagogic, antipyretic-antalgic, reduction cholesterol, diuresis.The Guangxi traditional Chinese medical science
Institute once carries out extraction and analysis and pharmacological evaluation to golden camellia tea to be proved, the water extraction of golden camellia tea has hypoglycemic, drop blood
Pressure, reducing blood lipid, drop cholesterol in serum, the tumour growth that suppresses, atherosclerosis, a variety of enzymes of human activin, raising flesh
The different physiological roles such as body immunocompetence, anti-aging.
(2) lotus leaf, it is nymphaeaceae plant lotus Nelumbo nucifera Gaertn. dried leaf.Record in Chinese Pharmacopoeia
2015
Year version：【Nature and flavor and channel tropism】Hardship, put down.Return liver, spleen, stomach.【Function is with curing mainly】Clearing away summer-heat and eliminating dampness, sending up the lucid yang are cool
Blood stops blooding.Mandrill, uterine bleeding of having blood in stool are told for hot summer weather polydipsia, summer heat damp diarrhea, splenasthenic diarrhea, blood-head.
(3) root of kudzu vine, it is legume pueraria lobata Pueraria lobata (Willd.) Ohwi dry root.Record in China
Pharmacopeia version in 2015：【Nature and flavor and channel tropism】It is sweet, pungent, it is cool.Returns spleen, stomach, lung channel.【Function is with curing mainly】Expelling pathogenic factors from muscles and skin is brought down a fever, and is promoted the production of body fluid to quench thirst,
Promoting eruption, Shengyang Zhixie is clearing and activating the channels and collaterals, relieving alcoholism.Had a headache for fever caused by exogenous pathogens, stiff nape and back is thirsty, quenches one's thirst, measles without adequate eruption, heat
Dysentery, diarrhea, dizziness and headache, hemiplegia, chest impediment and cardialgia, during wine poison is hindered.
(4) cassia seed, it is legume Cassia Cassia obtusifolia L.'s or little Cassia tora Cassia tora L.
Dry mature seed.Record in Chinese Pharmacopoeia version in 2015：【Nature and flavor and channel tropism】It is sweet, bitter, salty, it is slightly cold.Return liver, large intestine channel.【Work(
Can be with curing mainly】Heat-clearing improving eyesight, relax bowel.Secretly fail to understand for the puckery pain of hot eyes, the more tears of photophobia, dizziness of having a headache, mesh, constipation.
(5) hawthorn, it is rosaceous plant large-fruited Chinese hawthorn Crataegus pinnatifida Bge.var.major N.E.Br.
Or hawthorn Crataegus pinnatifida Bge. dry mature fruit.Record in Chinese Pharmacopoeia version in 2015：【Nature and flavor with
Channel tropism】It is sour, sweet, tepor.Returns spleen, stomach, Liver Channel.【Function is with curing mainly】Food digesting stomach fortifying, scattered stasis, change turbid lipid-loweringing.For meat
It is stagnant, gastral cavilty turgor, diarrhea dysentery abdominal pain, blood stasis closed, postpartum stasis, confidant sting, chest impediment and cardialgia, hernia pain, hyperlipidemia.
(6) mulberry leaf, it is moraceae plants mulberry Morus alba L. dried leaf.《Chinese Pharmacopoeia》Version is recorded within 2015：【Property
Taste channel tropism】It is sweet, bitter, tremble with fear.Return lung, Liver Channel.【Function is with curing mainly】Dispelling wind and heat from the body, clearing away the lungheat and moisturizing, clear liver and improve vision.For wind-heat sense
Emit, lung-heat type cough, dizziness headache, hot eyes is dim-sighted.
The content of the invention
The purpose of the present invention is increased year by year for hyperpietic, clinically bad using the method treatment of drug combination
The more present situation of reaction, there is provided a kind of composition of hypotensive, said composition have no toxic side effect, moreover it is possible to immunity of organisms is improved, can
It is long-term use of.
The technical solution adopted in the present invention is as follows：
A kind of composition of hypotensive, is made up of the component of following parts by weight：Golden camellia tea 1-5 parts, lotus leaf 1-5 parts, Pueraria lobota
Root 1-5 parts, cassia seed 1-5 parts, hawthorn 1-5 parts, mulberry leaf 1-5 parts.
The composition of hypotensive described above, most preferably preferably it is made up of the component of following parts by weight：3 parts of golden camellia tea, lotus
3 parts of leaf, 3 parts of the root of kudzu vine, 3 parts of cassia seed, 3 parts of hawthorn, 3 parts of mulberry leaf.
The composition of hypotensive described above, medicine, any formulation allowed on health food can be prepared into, such as：Medicinal tea,
Pill, granule, tablet, capsule, decoction, soft extract, oral liquid, syrup etc., are preferably made medicinal tea.
The method that medicinal tea is made in the composition of more than one hypotensives, comprises the following steps：
S1. golden camellia tea, lotus leaf, the root of kudzu vine, cassia seed, hawthorn, mulberry leaf, cleaning, drying are taken respectively；
S2. raw material is weighed according to following parts by weight：Golden camellia tea 1-5 parts, lotus leaf 1-5 parts, root of kudzu vine 1-5 parts, cassia seed 1-5
Part, hawthorn 1-5 parts, mulberry leaf 1-5 parts；
S3. the load weighted medicinal materials of step S2 are taken, are respectively crushed into fine powder, are sieved；
S4. step S3 fine powders are taken, are mixed, packing, are produced.
Further, the screen cloth under step S3 items used in the sifting step is preferably 80-100 mesh, and most preferably preferably 90
Mesh.
The composition of hypotensive described above, the purposes in food, medicine in preparation hypotensive.
The composition of hypotensive of the present invention, according to traditional Chinese medicine theory, with reference to the dialectical therapy of modern Chinese medicine, with country
The integration of drinking and medicinal herbs catalogue kind that the Ministry of Public Health announces is raw material, and scientific formula is rigorous, has the two-way function of nutrition and treatment concurrently, can grow
Phase takes, safe and healthy.
High blood pressure is under the jurisdiction of in traditional Chinese medicine the card such as " dizziness " " headache " category, and sick position is hollow in clear key, or brains, clear key
Lose and support, or convulsive seizure due to phlegm-fire superinverse, clear key is disturbed, it is in close relations with liver,spleen,kidney.Its cause of disease and feelings will, diet, work and rest are not normal related, disease
Machine belongs to asthenia in origin and asthenia in superficiality, simulataneous insufficiency and excessive more.Empty person is more based on internal injury, deficiency of qi and blood, kidney essence deficiency, and brains, which lose, supports；Real person it is more because
Asthenia in origin and asthenia in superficiality, can be the deficiency of liver-yin and kidney-yin, liver-yang is partially high, the clear key of wind-yang and up-boring；Or spleen insufficiency, retention of phlegmatic dampness and Yu Xue Bi resistance are clear
Key, primary treatments are nourishing liver and kidney, calming the liver, clearing liver fire, invigorating the spleen to dry etc..
The present invention is so that Camellia nitidissima is clearing heat and detoxicating, diuresis dampness removing；Lotus leaf clearing away summer-heat and eliminating dampness, sending up the lucid yang, cooling blood and hemostasis；Root of kudzu vine solution
Flesh is brought down a fever, and is promoted the production of body fluid to quench thirst, promoting eruption, and Shengyang Zhixie is clearing and activating the channels and collaterals；Cassia seed heat-clearing improving eyesight, relaxes bowel；Hawthorn digesting stomach invigorating,
Scattered stasis, change turbid lipid-loweringing；Mulberry leaf dispelling wind and heat from the body, clearing away the lungheat and moisturizing；Above-mentioned composition share gather altogether clearing liver fire, it is calming the liver,
Strengthening the spleen and replenishing qi, the work(of fluid dryness, have the effects such as mutual collaboration, too many levels, Mutiple Targets, multipath special in treatment hypertension
Point, human body yin-yang balancing is both adjusted, adjust the physiological equilibrium of regulating blood pressure system again, have the effect of good to hypertension.
The beneficial effects of the invention are as follows：
1. bulk drug is taken from food and " integration of drinking and medicinal herbs " kind, safe to use.
2. prescription is rigorous, the few power of medicine is special, has clearing liver fire, calming the liver, strengthening the spleen and replenishing qi, fluid dryness and other effects, tool
There are each flavour of a drug mutually to cooperate with, the action character such as too many levels, Mutiple Targets, multipath, both adjust human body yin-yang balancing, adjust blood pressure again
The physiological equilibrium of regulator control system, there is the effect of good to hypertension, treat total effective rate up to more than 96%.
3. overcoming Western medicine takes medicine that species is more, and side effect is big, and adverse reaction is more when treating high blood pressure disease drug combination
The shortcomings of, medicine and health food can be used as long-term use of, safely and effectively.
Embodiment
With reference to specific embodiment, the invention will be further described, but does not limit the scope of the invention and apply
Scope：
First, the preparation of the composition medicinal tea of hypotensive
Embodiment 1
A kind of method that medicinal tea is made in composition of hypotensive, comprises the following steps：
S1. golden camellia tea, lotus leaf, the root of kudzu vine, cassia seed, hawthorn, mulberry leaf, cleaning, drying are taken respectively；
S2. raw material is weighed according to following parts by weight：Golden camellia tea 1000g, lotus leaf 1000g, root of kudzu vine 1000g, cassia seed
1000g, hawthorn 1000g, mulberry leaf 1000g；
S3. the load weighted medicinal materials of step S2 are taken, are respectively crushed into fine powder, cross 80 mesh sieves；
S4. step S3 fine powders are taken, are mixed, packing, are produced.
Embodiment 2
A kind of method that medicinal tea is made in composition of hypotensive, comprises the following steps：
S1. golden camellia tea, lotus leaf, the root of kudzu vine, cassia seed, hawthorn, mulberry leaf, cleaning, drying are taken respectively；
S2. raw material is weighed according to following parts by weight：Golden camellia tea 3000g, lotus leaf 3000g, root of kudzu vine 3000g, cassia seed
3000g, hawthorn 3000g, mulberry leaf 3000g；
S3. the load weighted medicinal materials of step S2 are taken, are respectively crushed into fine powder, cross 90 mesh sieves；
S4. step S3 fine powders are taken, are mixed, packing, are produced.
Embodiment 3
A kind of method that medicinal tea is made in composition of hypotensive, comprises the following steps：
S1. golden camellia tea, lotus leaf, the root of kudzu vine, cassia seed, hawthorn, mulberry leaf, cleaning, drying are taken respectively；
S2. raw material is weighed according to following parts by weight：Golden camellia tea 5000g, lotus leaf 5000g, root of kudzu vine 5000g, cassia seed
5000g, hawthorn 5000g, mulberry leaf 5000g；
S3. the load weighted medicinal materials of step S2 are taken, are respectively crushed into fine powder, cross 100 mesh sieves；
S4. step S3 fine powders are taken, are mixed, packing, are produced.
The effect of below by way of animal experiment to illustrate the present composition.
2nd, animal experiment
1. antihypertensive function is tested
1.1 test material
1.1.1 sample：The product of embodiment 1, while using commercially available Captopril tablets as positive control.
1.1.2 experimental animal：Grow up spontaneous hypertensive rat (SHR) rat, SD rats, male, 12 week old, body weight
180g±20g。
1.1.3 instrument：RBP-1 type rat blood pressure meters.
Blood pressure, each measurement interval certain time are determined with tail pulses method, recorded heart rate changes≤10 times/min, blood pressure becomes
Change<6mmHg continuous 3 readings, take its mean.Blood pressure and heart rate are determined since being given animal subject once daily, continuously
45d。
1.2 test method
1.2.1 the preparation of given the test agent solution
The preparation of test group need testing solution：The product content thing 80g of Example 1, add the purified water boiled to soak, treat cold
But filtered after room temperature, filtrate is settled to 200ml, as 0.4g/ml, and this is high dose group；Then high dose group solution 100ml is taken
Add purified water to 200ml, as middle dose group；Middle dose group solution 100ml is finally taken to add purified water to 200ml, as low dose
Amount group.Gavage volume is 10ml/kgBW.
The preparation of positive control need testing solution：Captopril tablets 150mg is taken, adds purified water to make dissolving and is settled to
200ml, as 0.75mg/ml.
1.2.2 packet and administration
32 SHR rats are randomly divided into 4 groups：High, medium and low three dosage treatment groups, positive control (captopril) group,
Every group 8；It is normal group and SHR groups using SD rats and SHR as control.High, medium and low three treatment groups dosage difference
For 4g/kgbw, 2g/kgbw, 1g/kgbw, positive control (Captopril group) dosage is 15mg/kgbw, and SHR groups are equal
The purified water of same volume is given, normal group gives 4g/kgbw (high dose), 1 time a day, treats 45d altogether.
1.3 statistical procedures
Each group of data is handled with SPSS13.0 statistical softwares, and measurement data represents that multigroup is compared using Dan Yin with x ± s
Plain variance analysis (ANOVA), compare between two groups and examined using q.
1.4 result
1.4.1 the front and rear blood pressure contrast of each group rat administration
It the results are shown in Table 1.
The front and rear blood pressure contrast (x ± s, n=8) of each group rat of table 1 administration
Note：△ △ represent the P compared with normal group<0.01；#, ## represent the P compared with before being administered<0.05, P<0.01
As shown in Table 1, after administration, compared with model group, the diastolic pressure of 3 dosage groups and Captopril group rat, shrink
Pressure is remarkably decreased (P<0.01 or P<0.05)；Compared with before administration, 3 dosage and Captopril group can significantly reduce rat
Systolic pressure and diastolic pressure (P<0.01 or P<0.05).Show that the embodiment of the present invention 1 is respectively provided with obvious drop blood with captopril
Pressure acts on.
1.4.2 the comparison of heart rate before and after each group rat is administered
It the results are shown in Table 2.
The contrast (x ± s, n=8) of heart rate before and after the administration of each group rat of table 2
As shown in Table 2, it is not statistically significant that forward and backward each group heart rate difference is administered, illustrates the present composition to heart rate
Influence it is little.
3rd, clinical practice is tested
1. treat hypertension
1.1 case selection standard
Primary hypertension patient, non-medication, or take hypertension drug but be discontinued after week two-by-two, diastolic pressure >=
90mmHg, systolic pressure >=140mmHg, meet both any one.
Exclusion standard
(1) age is in under-18s or over-65s person；
(2) gestational period or women breast-feeding their children；
(3) merge intentionally, brain, liver, severe systemic disease patient, the mental patient such as kidney and hemopoietic system；
(4) secondary hypertension patient；
(5) allergic constitution or to multi-medicament allergy sufferers.
1.2 medication
152 hyperpietics (wherein man 89, female 63) for meeting above-mentioned standard are randomly divided into by medical order
Embodiment group and positive controls, every group 76.
(1) embodiment group：Embodiment 1-3 samples are prepared by above-mentioned, for clinical test.Orally, take sample 2 to wrap, add
Water 500-1000ml boils 3-5 minutes, and a point morning and evening finishes off.The course for the treatment of：Medication 6 weeks.
(2) control group：Captopril tablets.Orally, the 1-3 days：Each 12.5mg；The 4-7 days, each 25mg (1), often
Day 2-3 times；2nd week：Each 50mg (2), it is daily 2-3 times.The course for the treatment of：Medication 6 weeks.
1.3 curative effect determinate standard
(1) it is effective：More than diastole drops 10mmHg, and reach normal range (NR)；Or though systolic pressure does not drop to normal level
But 20mmHg or more is declined.
(2) effectively：Diastole drops have reached normal range (NR) not as good as 10mmHg；Or diastolic pressure relatively treats preceding decline 10-
19mmHg, but not up to normal range (NR)；Systolic pressure declines more than 30mmHg (possessing any one) before relatively treating.
(3) it is invalid：Not up to above standard person.
1.4 treatment results
It the results are shown in Table 3.
Therapeutic evaluation situation before and after the 1-3 of the embodiment of the present invention of table 3 and Captopril Treatment hyperpietic's medication
During being tested more than, the indexs such as front and rear blood routine, routine urinalysis, darling renal function are tested to subject and carried out
Check, embodiment group is no abnormal, and the uncomfortable reaction such as allergy occurs in none case；And control group has 5 patients
There are the adverse reactions such as pruitus, heating, palpitaition.
From table 3, embodiment group has significant difference (P ＜ 0.05) compared with the antihypertensive effect after control group treatment.
Group of embodiment of the present invention sample is taken after 6 weeks, blood pressure significantly decreases, the treatment total effective rate to hypertension reach 96% with
On, higher than control group, and do not occur any adverse reaction during testing, illustrate that the present composition has drop blood well
Pressure acts on, safe to use effective.It is typical example below：
Exemplary 1：Lee, man, 63 years old, cause dizziness in 3 years was gone to see a doctor, and is diagnosed as essential hypertension.Take
Western medicine of depressurization more than a year, because side effect is withdrawn greatly, after withdrawing Western medicine, often feels that uncomfortable in chest, nervous, shortness of breath, sleep are bad.Clothes
With the sample of the embodiment of the present invention 2, take sample 2 to wrap daily, add water 500-1000ml to boil 3-5 minutes, a point morning and evening finishes off, and takes 3
After it, symptom mitigation, measuring blood pressure systolic pressure is down to 148mmHg by 157mmHg, and diastolic pressure is down to 78mmHg by 86mmHg.Followed by
Continue after taking 12 days, measuring blood pressure systolic pressure is 138mmHg, and diastolic pressure 73mmHg, after continuously having taken 6 weeks, blood pressure is tieed up always
Hold and blood pressure rise phenomenon do not occur to paying a return visit after 1 year in normal range (NR).
Exemplary 2：Agriculture, female, 58 years old, dizzy more than 10 years, essential hypertension is the discovery that during to Hospital Physical Examination.Almost
All western medicine of depressurization were taken, but blood pressure could not be down to normally always.Take 1 sample of the embodiment of the present invention 15 days, take daily
Sample 2 wraps, and adds water 500-1000ml to boil 3-5 minutes, and a point morning and evening finishes off, and review result hypertension is by taking the embodiment of the present invention
147 before sample are down to 107, and low pressure is down to 89 by 95, and after continuously having taken 6 weeks, blood pressure maintains normal range (NR) to after 1 year
Return visit does not occur blood pressure rise phenomenon.
Exemplary 3：Certain is revived, man, 56 years old, is diagnosed as essential hypertension 5 years.Western medicine of depressurization is taken 2 years, because decompression
The reasons such as effect is bad and side effect is big, seek treatment by Chinese herbs.The sample of the embodiment of the present invention 3 is taken, takes sample 2 to wrap daily, adds
Water 500-1000ml boils 3-5 minutes, and a point morning and evening is finished off, and after taking 10 days, measuring blood pressure systolic pressure is down to by 167mmHg
158mmHg, diastolic pressure are down to 92mmHg by 101mmHg.It is further continued for after taking 20 days, measuring blood pressure systolic pressure is 145mmHg, diastole
Press as 89mmHg, after continuously having taken 6 weeks, blood pressure maintains normal range (NR) always, and to paying a return visit after 1 year, blood pressure rise do not occur existing
As.
Claims (10)
1. a kind of composition of hypotensive, it is characterised in that be made up of the raw material of following parts by weight：Golden camellia tea 1-5 parts, lotus leaf
1-5 parts, root of kudzu vine 1-5 parts, cassia seed 1-5 parts, hawthorn 1-5 parts, mulberry leaf 1-5 parts.
2. the composition of hypotensive according to claim 1, it is characterised in that be made up of the raw material of following parts by weight：Golden flower
3 parts of tealeaves, 3 parts of lotus leaf, 3 parts of the root of kudzu vine, 3 parts of cassia seed, 3 parts of hawthorn, 3 parts of mulberry leaf.
3. the composition of hypotensive according to claim 1 or claim 2, it is characterised in that food or medicine is made in the composition
The acceptable any formulation in field.
4. the composition of hypotensive according to claim 3, it is characterised in that medicinal tea, pill, particle is made in the composition
Agent, tablet, capsule, decoction, soft extract, oral liquid, syrup.
5. the composition of hypotensive according to claim 4, it is characterised in that medicinal tea is made in the composition.
6. a kind of method that medicinal tea is made in composition of hypotensive according to claim 5, it is characterised in that including following step
Suddenly：
S1. golden camellia tea, lotus leaf, the root of kudzu vine, cassia seed, hawthorn, mulberry leaf, cleaning, drying are taken respectively；
S2. raw material is weighed according to following parts by weight：Golden camellia tea 1-5 parts, lotus leaf 1-5 parts, root of kudzu vine 1-5 parts, cassia seed 1-5 parts,
Hawthorn 1-5 parts, mulberry leaf 1-5 parts；
S3. the load weighted medicinal materials of step S2 are taken, are respectively crushed into fine powder, are sieved；
S4. step S3 fine powders are taken, are mixed, packing, are produced.
7. the method that medicinal tea is made in the composition of hypotensive according to claim 6, it is characterised in that raw materials used moisture contains
Amount≤8.5%.
8. the method that medicinal tea is made in the composition of hypotensive according to claim 6, it is characterised in that sieving described in step S3
Screen cloth used in step is 80-100 mesh.
9. the method that medicinal tea is made in the composition of hypotensive according to claim 8, it is characterised in that sieving described in step S3
Screen cloth used in step is 90 mesh.
10. according to the composition of any hypotensive in claim 1-9, it is characterised in that the composition is preparing drop
Purposes in the food of blood pressure, medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710488515.4A CN107334870A (en) | 2017-06-23 | 2017-06-23 | A kind of composition of hypotensive and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710488515.4A CN107334870A (en) | 2017-06-23 | 2017-06-23 | A kind of composition of hypotensive and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107334870A true CN107334870A (en) | 2017-11-10 |
Family
ID=60221167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710488515.4A Pending CN107334870A (en) | 2017-06-23 | 2017-06-23 | A kind of composition of hypotensive and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107334870A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019127439A (en) * | 2018-01-22 | 2019-08-01 | 株式会社お茶村 | Supplement comprising morus alba leaves |
| CN111603542A (en) * | 2020-06-15 | 2020-09-01 | 罗炳常 | A Chinese medicinal composition and its preparation method |
| CN112516206A (en) * | 2020-12-24 | 2021-03-19 | 中国科学院城市环境研究所 | Composition for reducing high blood pressure, high blood sugar and high blood fat, traditional Chinese medicine preparation and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939418A (en) * | 2005-09-30 | 2007-04-04 | 张晓峰 | Chinese medicinal herb composition with food and medicine consangunity |
| CN101450129A (en) * | 2007-11-30 | 2009-06-10 | 北京因科瑞斯医药科技有限公司 | Traditional Chinese medicine composition with blood-pressure reduction and blood-fat reduction function |
| CN103446426A (en) * | 2013-01-14 | 2013-12-18 | 贾晋科 | Chinese medicine tea capable of lowering blood pressure and reducing blood fat |
| CN101755972B (en) * | 2010-01-20 | 2014-03-26 | 广西桂人堂金花茶产业集团股份有限公司 | Processing method of Camellia chrysantha(Hu)Tuyama |
-
2017
- 2017-06-23 CN CN201710488515.4A patent/CN107334870A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939418A (en) * | 2005-09-30 | 2007-04-04 | 张晓峰 | Chinese medicinal herb composition with food and medicine consangunity |
| CN101450129A (en) * | 2007-11-30 | 2009-06-10 | 北京因科瑞斯医药科技有限公司 | Traditional Chinese medicine composition with blood-pressure reduction and blood-fat reduction function |
| CN101755972B (en) * | 2010-01-20 | 2014-03-26 | 广西桂人堂金花茶产业集团股份有限公司 | Processing method of Camellia chrysantha(Hu)Tuyama |
| CN103446426A (en) * | 2013-01-14 | 2013-12-18 | 贾晋科 | Chinese medicine tea capable of lowering blood pressure and reducing blood fat |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019127439A (en) * | 2018-01-22 | 2019-08-01 | 株式会社お茶村 | Supplement comprising morus alba leaves |
| CN111603542A (en) * | 2020-06-15 | 2020-09-01 | 罗炳常 | A Chinese medicinal composition and its preparation method |
| CN112516206A (en) * | 2020-12-24 | 2021-03-19 | 中国科学院城市环境研究所 | Composition for reducing high blood pressure, high blood sugar and high blood fat, traditional Chinese medicine preparation and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105031517A (en) | Dendrobium officinale healthcare tea capable of reducing blood fat, blood sugar, and blood pressure and preparation method thereof | |
| CN107334870A (en) | A kind of composition of hypotensive and preparation method thereof | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN104799177A (en) | Sweet potato-based nutritious porridge and preparation method | |
| CN102940730A (en) | Traditional Chinese medicine for treating hypertension | |
| CN109528953A (en) | There is a kind of pair of microcirculation in human body the grass that crosses of improvement result to collect Chinese medicine plant composition | |
| CN106173605A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Herba Dendrobii | |
| CN106822583A (en) | A kind of regulation blood pressure, blood fat, Chinese medicine composition of blood sugar and preparation method thereof | |
| CN104206595A (en) | Blood lipid and blood glucose reducing Chinese wolfberry root-bark health care tea and preparation method thereof | |
| CN102293855A (en) | Chinese medicinal composition for treating speech and kidney deficiency diabetic nephropathy, and preparation method and application thereof | |
| CN106177054A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae | |
| CN108355055A (en) | A kind of pharmaceutical composition for treating hypertension | |
| CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN107281390A (en) | It is a kind of for Chinese medicine composition of health care and preparation method thereof | |
| CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae | |
| CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
| CN105998198B (en) | Health-care product for improving hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN104673573A (en) | Wine with diabetes prevention and treatment function and preparation method thereof | |
| CN104984150A (en) | Preparing technology of health maintaining porridge with blood pressure reducing effect | |
| CN106902250A (en) | A kind of compound medicine of traditional Chinese and western medicine therapeutic alliance diabetes | |
| CN106728828A (en) | A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease | |
| CN105727243A (en) | Chinese herbal composition for treating myocarditis and preparing method of Chinese herbal composition | |
| CN105267815A (en) | Spray for treating infant lung-kidney-deficiency type asthma and preparing method thereof | |
| CN104706942A (en) | Medicine composition for treating cerebrocardiac syndrome and preparation method of medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171110 |
|
| RJ01 | Rejection of invention patent application after publication |